Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07418736 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase II Study of CM326 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease

Name: A Phase II Study of CM326 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease — clinical trial record (NCT07418736)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 2

SponsorCSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Started2025-12-18

View on ClinicalTrials.gov ↗

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

42 trials monitored

See 1 trial at risk

COPD

1,057 trials monitored

See 28 trials at risk

This study is a multi-center, randomized, double-blind, placebo-controlled Phase II clinical study to evaluate the efficacy, safety, PK characteristics, PD effects and immunogenicity of CM326 in subjects with moderate to Severe Chronic Obstructive Pulmonary Disease. The study consists of a screening period of up to 4 weeks, a randomized treatment period of 24 to 52 weeks, and a 12-week safety follow-up period.

Trial Details

NCT Number	NCT07418736
Lead Sponsor	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Conditions	Chronic Obstructive Pulmonary Disease
Enrollment	318 participants
Start Date	2025-12-18
Primary Completion	2027-07-01 (estimated)
Study Completion	2027-10-10 (estimated)
Updated on ClinicalTrials.gov	2026-02-18